ReviewMicrobiologyOpen2026
Nanoparticle-Based Strategies to Combat Multidrug-Resistant Bacteria: Mechanisms, Applications, and Future Perspectives.
Review in MicrobiologyOpen, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The infectious diseases remain a primary cause of morbidity and mortality on a global level, a crisis exacerbated by the rapid emergence of antimicrobial resistance (AMR). The ineffectiveness of the old antibiotics and the stagnation of the development of new medications have triggered an emergency in the search for new methods of treatment. This review examines the opportunity of nanotechnology, which is the so-called nanobiotics, as a game-changing technology in combating multidrug-resistant (MDR) bacteria by searching various databases. Nanoparticles (NPs) are unique physicochemicals, i.e., high surface-to-volume ratio and multi-valent properties that enable them to overcome traditional resistance, e.g., efflux pumps, target modifications. The paper discusses the important antibacterial processes, which can involve the induction of oxidative stress by the production of reactive oxygen species (ROS), the physical destabilization of the bacterial cell envelope, or the targeting of intracellular macromolecules, such as DNA and proteins. Moreover, it emphasizes the synergistic nature of the interactions of NPs with traditional antibiotics to improve drug delivery and efficacy and decrease host toxicity. Although a wide range of nanomaterials, such as silver, gold, metal oxides, and carbon-based structures, promise a lot, a lot of questions have been raised on their compatibility in the long term, their impact on the environment, and their legality. Nanotechnology, coupled with precision medicine and CRISPR-based systems, is a promising future in dealing with infectious diseases. Finally, nanomedicine is a complex solution to address the shortcomings of existing treatments and achieve a future of world health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.